Osteomalacia as a late metabolic complication of ifosfamide chemotherapy in young adults: Illustrative cases and review of the literature

Sarcoma

Volumn 2007, Issue , 2007, Pages

  Church, D N ^a   Hassan, A B ^b   Harper, S J ^c   Wakeley, C J ^d   Price, C G A ^a  

^a BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c SOUTHMEAD HOSPITAL   (United Kingdom)

^d BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; GENTAMICIN; IFOSFAMIDE; POTASSIUM; VINCRISTINE; VITAMIN D;

ADULT; ANKLE FRACTURE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; EWING SARCOMA; FEBRILE NEUTROPENIA; FEMALE; FIBULA GRAFT; HUMAN; HYPOKALEMIA; HYPOPHOSPHATEMIA; KIDNEY INJURY; KIDNEY TUMOR; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHRECTOMY; NEPHRON; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEODYSTROPHY; OSTEOMALACIA; PRIORITY JOURNAL; RADIODIAGNOSIS; RISK FACTOR; SOFT TISSUE SARCOMA; STRESS FRACTURE; TUBULAR DYSFUNCTION;

EID: 34250854608     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2007/91586     Document Type: Article

References (43)

1. V. H. C. Bramwell H. T. Mouridsen A. Santoro Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. European Journal of Cancer and Clinical Oncology 23 3 1987 311 321
2. K. H. Antman L. Ryan A. Elias D. Sherman H. E. Grier Response to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcoma. Journal of Clinical Oncology 7 1 1989 126 131
3. S. R. Patel S. Vadhan-Raj M. A. Burgess Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. American Journal of Clinical Oncology 21 3 1998 317 321
4. P. Bruhl H. Hoefer-Janker W. Scheef W. Vahlensieck Prophylactic alkalization of the urine during cytostatic tumor treatment with the oxazaphosphorine derivatives, cyclophosphamide and ifosfamide. Onkologie 2 1979 3 120 124
5. W. Scheef H. O. Klein N. Brock Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results. Cancer Treatment Reports 63 3 1979 501 505
6. R. Skinner Roderick.Skinner@ncl.ac.uk Chronic ifosfamide nephrotoxicity in children. Medical and Pediatric Oncology 41 3 2003 190 197
7. R. Skinner I. M. Sharkey A. D. J. Pearson A. W. Craft Ifosfamide, mesna, and nephrotoxicity in children. Journal of Clinical Oncology 11 1 1993 173 190
8. J. W. Foreman K. S. Roth Human renal Fanconi syndrome - then and now. Nephron 51 3 1989 301 306
9. D. W. Cockcroft M. H. Gault Prediction of creatinine clearance from serum creatinine. Nephron 16 1 1976 31 41
10. S. J. Strauss A. McTiernan D. Driver Single center experience of a new intensive induction therapy for ewing's family of tumors: feasibility, toxicity, and stem cell mobilization properties. Journal of Clinical Oncology 21 15 2003 2974 2981
11. C. B. Pratt W. H. Meyer J. J. Jenkins Ifosfamide, Fanconi's syndrome, and rickets. Journal of Clinical Oncology 9 8 1991 1495 1499
12. M. S. Ashraf J. Brady F. Breatnach P. F. Deasy A. O'Meara Ifosfamide nephrotoxicity in paediatric cancer patients. European Journal of Pediatrics 153 2 1994 90 94
13. R. Rossi A. Godde A. Kleinebrand Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients. Journal of Clinical Oncology 12 1 1994 159 165
14. R. Skinner S. J. Cotterill M. C. G. Stevens Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group. British Journal of Cancer 82 10 2000 1636 1645
15. F. Marinez G. Deray P. Cacoub H. Beaufils C. Jacobs Ifosfamide nephrotoxicity: deleterious effect of previous cisplatin administration. The Lancet 348 9034 1996 1100 1101
16. R. Rossi A. Godde A. Kleinebrand B. Rath H. Jurgens Concentrating capacity in ifosfamide-induced severe renal dysfunction. Renal Failure 17 5 1995 551 557
17. R. Skinner A. D. J. Pearson M. W. English Risk factors for ifosfamide nephrotoxicity in children. The Lancet 348 9027 1996 578 580
18. M. J. Zamlauski-Tucker M. E. Morris J. E. Springate Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney. Toxicology and Applied Pharmacology 129 1 1994 170 175
19. M. Mohrmann S. Ansorge U. Schmich B. Schonfeld M. Brandis Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture. Pediatric Nephrology 8 2 1994 157 163
20. J. E. Springate Ifosfamide metabolite chloroacetaldehyde causes renal dysfunction in vivo. Journal of Applied Toxicology 17 1 1997 75 79
21. L. Dubourg C. Michoudet P. Cochat G. Baverel Human kidney tubules detoxify chloroacetaldehyde, a presumed nephrotoxic metabolite of ifosfamide. Journal of the American Society of Nephrology 12 8 2001 1615 1623
22. M. Mohrmann S. Ansorge B. Schonfeld M. Brandis Dithio-bis- mercaptoethanesulphonate (DIMESNA) does not prevent cellular damage by metabolites of ifosfamide and cyclophosphamide in LLC- PK 1 cells. Pediatric Nephrology 8 4 1994 458 465
23. C. D. Burk I. Restaino B. S. Kaplan A. T. Meadows Ifosfamide-induced renal tubular dysfunction and rickets in children with Wilms tumor. Journal of Pediatrics 117 2 part 1 1990 331 335
24. A. Suarez H. McDowell P. Niaudet E. Comoy F. Flamant Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report. Journal of Clinical Oncology 9 12 1991 2177 2182
25. R. Loebstein G. Koren Ifosfamide-induced nephrotoxicity in children: critical review of predictive risk factors. Pediatrics 101 6 1998 E8
26. N. M. Marina C. A. Poquette A. M. Cain D. Jones C. B. Pratt W. H. Meyer Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas. Journal of Pediatric Hematology/Oncology 22 2 2000 112 118
27. R. Skinner A. D. J. Pearson L. Price M. G. Coulthard A. W. Craft Nephrotoxicity after ifosfamide. Archives of Disease in Childhood 65 7 1990 732 738
28. R. Rossi A. Kleinbrand A. Godde B. Rath H. Jurgens Increased risk of ifosfamide-induced renal Fanconi's syndrome after unilateral nephrectomy. The Lancet 341 8847 1993 755
29. A. V. Boddy M. English A. D. J. Pearson J. R. Idle R. Skinner Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics. European Journal of Cancer - Part A 32 7 1996 1179 1184
30. R. Rossi P. Schafers J. Pleyer C. Postler J. Boos H. Jurgens The influence of short versus continuous ifosfamide infusion on the development of renal tubular impairment. International Journal of Pediatric Hematology/Oncology 4 4 1997 393 399
31. R. M. Rossi C. Kist U. Wurster W.-R. Kulpmann J. H. H. Ehrich Estimation of ifosfamide/cisplatinum-induced renal toxicity by urinary protein analysis. Pediatric Nephrology 8 2 1994 151 156
32. J. Z. Melnick M. Baum J. R. Thompson Aminoglycoside-induced Fanconi's syndrome. American Journal of Kidney Diseases 23 1 1994 118 122
33. H. N. Caron N. Abeling A. van Gennip J. de Kraker P. A. Voucte Hyperaminoaciduria identifies patients at risk of developing renal tubular toxicity associated with ifosfamide and platinate containing regimens. Medical and Pediatric Oncology 20 1 1992 42 47
34. R. Rossi Nephrotoxicity of ifosfamide - moving towards understanding the molecular mechanisms. Nephrology Dialysis Transplantation 12 6 1997 1091 1092
35. S. van Gool P. Brock G. Wijndaele Reversible hypophosphatemic rickets following ifosfamide treatment. Medical and Pediatric Oncology 20 3 1992 254 257
36. V. K. Prasad I. J. Lewis S. R. Aparicio Progressive glomerular toxicity of ifosfamide in children. Medical and Pediatric Oncology 27 3 1996 149 155
37. A. A. Garcia Ifosfamide-induced Fanconi syndrome. Annals of Pharmacotherapy 29 6 1995 590 591
38. A. Negro G. Regolisti F. Perazzoli S. Davoli C. Sani E. Rossi Ifosfamide-induced renal Fanconi syndrome with associated nephrogenic diabetes insipidus in an adult patient. Nephrology Dialysis Transplantation 13 6 1998 1547 1549
39. C. Beckwith K. K. Flaharty A. K. Cheung P. G. Beatty Fanconi's syndrome due to ifosfamide. Bone Marrow Transplantation 11 1 1993 71 73
40. L. Duck J.-P. Devogelaer A. Persu Osteomalacia due to chemotherapy-induced Fanconi syndrome in an adult patient. Gynecologic Oncology 98 2 2005 329 331
41. R. Skinner A. D. J. Pearson M. G. Coulthard Assessment of chemotherpy-associated nephrotoxicity in children with cancer. Cancer Chemotherapy and Pharmacology 28 2 1991 81 92
42. M. Rehling M. L. Moller B. Thamdrup Simultaneous measurement of renal clearance and plasma clearance of T 99 m c -labelled diethylenetriaminepenta- acetate, C 51 r -labelled ethylenediaminetetra-acetate and inulin in man. Clinical Science 66 5 1984 613 619
43. E. Berman bermane@mskcc.org M. Nicolaides R. G. Maki Altered bone and mineral metabolism in patients receiving imatinib mesylate. New England Journal of Medicine 354 19 2006 2006 2013